Zymeworks Appoints Antibody and Drug Development Expert Dr. Paul J. Carter to its Scientific Advisory Board

14 Apr 2009

·www.biospace.com

Antibody

VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Dr. Paul J. Carter, Chief Scientific Officer of VLST Corp., to its scientific advisory board.

Organizations

Zymeworks BC, Inc.

Viral Logic Systems Technology Corp.

Indications

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.